(Q41489196)

English

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

scientific article published on 15 November 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

phase III clinical trial

0 references

0 references

placebo-controlled trial

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

5

object named as

Karim Fizazi

1 reference

Europe PubMed Central

1 October 2017

PMC publication ID

2

object named as

Fred Saad

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

author name string

Matthew R Smith

1

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Robert Coleman

3

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Neal Shore

4

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Bertrand Tombal

6

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Kurt Miller

7

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Paul Sieber

8

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Lawrence Karsh

9

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Ronaldo Damião

10

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Teuvo L Tammela

11

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Blair Egerdie

12

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Hendrik Van Poppel

13

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Joseph Chin

14

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Juan Morote

15

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Francisco Gómez-Veiga

16

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Tomasz Borkowski

17

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Zhishen Ye

18

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Amy Kupic

19

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Roger Dansey

20

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Carsten Goessl

21

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

language of work or name

0 references

publication date

15 November 2011

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

379

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

9810

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

39-46

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Examining the Metastatic Niche: Targeting the Microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

AACR centennial series: the biology of cancer metastasis: historical perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

NCCN clinical practice guidelines in oncology: prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

NCCN Task Force Report: Bone Health in Cancer Care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

The RANK/RANKL/OPG triad in cancer-induced bone diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Regulation of cancer cell migration and bone metastasis by RANKL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Androgen deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Mechanisms of bone metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Clinical course and prognostic factors following bone recurrence from breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Skeletal complications of malignancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

11 June 2018

Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

19 August 2018

Androgen deprivation for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

19 August 2018

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

19 August 2018

Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

19 August 2018

Oral Sodium Clodronate for Nonmetastatic Prostate Cancer--Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671878

2 December 2018

Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961226-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cervical actinomycosis with spinal cord compression. Case report and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961226-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(11)61226-9

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41489196&oldid=1966841897"